RESUMO
Gastric cancer is a common type of malignant tumor. Recently, a growing number of clinical researches initiated by investigators have provided valuable evidence for clinical practice. Here we review the perioperative treatment of locally advanced gastric cancer, and summarize the optimization of neoadjuvant treatment regimens, the exploration of new combinational treatment models and new adjuvant chemotherapy schemes, and the changes in the status of chemoradiotherapy in adjuvant therapy. At the same time, for the comprehensive treatment of advanced gastric cancer, the advances in the optimization of first-line chemotherapy regimens, emerging immunotherapy and targeted therapy are reviewed as well. Gastric cancer is a highly heterogeneous tumor. For further development of precision medicine represented by targeted therapy and immunotherapy, genetic testing-guided precise molecular subtyping will be the direction.
Assuntos
Antineoplásicos/uso terapêutico , Quimiorradioterapia/tendências , Terapia Neoadjuvante/tendências , Neoplasias Gástricas/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica , Quimioterapia Adjuvante , Gastrectomia , HumanosRESUMO
Gastric cancer is a common type of malignant tumor. Recently, a growing number of clinical researches initiated by investigators have provided valuable evidence for clinical practice. Here we review the perioperative treatment of locally advanced gastric cancer, and summarize the optimization of neoadjuvant treatment regimens, the exploration of new combinational treatment models and new adjuvant chemotherapy schemes, and the changes in the status of chemoradiotherapy in adjuvant therapy. At the same time, for the comprehensive treatment of advanced gastric cancer, the advances in the optimization of first-line chemotherapy regimens, emerging immunotherapy and targeted therapy are reviewed as well. Gastric cancer is a highly heterogeneous tumor. For further development of precision medicine represented by targeted therapy and immunotherapy, genetic testing-guided precise molecular subtyping will be the direction.
RESUMO
Objective To explore the electrophysiological examination results and risk factors of type 2 diabetic peripheral neuropathy. Methods 337 patients with type 2 diabetes from August 2014 to December 2016 in the first people's hospital in Shizuishan city were divided into DPN group (n=218) and NPDN group(n=119) according to the results of NCV and SSR examinations. The general information and laboratory biochemical indicators in the two groups were compared. Multivariate Logistic regression was used to analyze the risk factors of DPN. Results The diagnosis rate of DPN detected by NCV combined with SSR was higher than that of NCV or SSR alone(P<0.05);There were significant differences in age,duration of diabetes,history of hypertension,systolic blood pressure,2h FBG,HbA1c,FINS,2 h INS,FC-P, 2h FC-P,ACR between the DPN group and NPDN group(P<0.05);Logistic multivariable analysis showed that age, duration of diabetes, 2h FBG, HbA1c, ACR were independent risk factors for DPN. Conclusion It is beneficial to increase the diagnosis rate of DPN by NCV combined with SSR. There is a higher incidence rate of DPN type 2 diabetes patients with older grade, longer duration of diabetes, higher 2h FBG, HbA1c and ACR.